Multiplexed blood biomarkers for Alzheimer’s disease subtypes
Official title: Highly Multiplexed Extracellular Vesicle Analysis for Alzheimer's Disease
Funded at Numentus Technologies INC. · NIH-11409249 · Data updated 2026-11-12
A new test uses many extracellular vesicle signals from blood to help identify different Alzheimer’s subtypes and guide better diagnosis.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Numentus Technologies INC. NIH-funded |
| Lab location | 1 site (Menlo Park, United States) |
| Project start | September 17, 2026 |
| Project end | September 16, 2027 |
| Funding year | 2026 |
| Award (this year) | $304,788 |
| NIH project number | 1R43AG097312-01A1 |
| Project ID | NIH-11409249 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for or diagnosed with Alzheimer’s disease or related dementias who are willing to provide blood samples for biomarker analysis.
✕Less likely to help
Patients whose disease is not related to the brain or who cannot provide blood samples may not benefit directly.
What this research studies
This project aims to develop a blood-based biomarker approach using extracellular vesicles to capture brain-derived information, potentially revealing multiple Alzheimer’s subtypes. By analyzing a broad panel of indicators, the study seeks to overcome the limitations of single biomarkers and improve diagnostic reliability. If successful, this work could lead to earlier and more accurate detection and better guidance for personalized treatment decisions.
Why it matters
Potential benefit: Could enable more accurate and earlier diagnosis and support personalized treatment planning for people with Alzheimer’s disease.
How similar studies have gone: Other groups have shown promise with EV-based biomarkers, but a comprehensive multiplex approach remains exploratory and may yield new insights.
Where this research is happening
-
Numentus Technologies INC.
Menlo Park, United States Active
Researchers
- Principal investigator: Faris, Gregory W — Numentus Technologies INC.
- Study coordinator: Faris, Gregory W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.